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Abstract
Chronic inflammation fundamentally influences cancer risk and development. A mechanism
of chronic inflammation is the formation of inflammasome complexes which results in the
sustained secretion of the pro-inflammatory cytokines IL1β and IL18. Inflammasome
expression and actions vary among cancers. There is no information on inflammasome
expression in ovarian cancer (OvCa). To determine if ovarian tumors express inflamma-
some components, mRNA and protein expression of NLRP3 (nucleotide-binding domain,
leucine-rich repeat family, pyrin domain containing 3), caspase-1, IL1β, and IL18 expression
in hen and human OvCa was assessed. Chicken (hen) OvCa a valid model of spontaneous
human OvCa. Hens were selected into study groups with or without tumors using ultraso-
nography; tumors were confirmed by histology, increased cellular proliferation, and ex-
pression of immune cell marker mRNA. mRNA expression was higher for hallmarks of
inflammasome activity (caspase-1, 5.9x increase, p = 0.04; IL1β, 4x increase, p = 0.04; and
IL18, 7.8x increase, p = 0.0003) in hen OvCa compared to normal ovary. NLRP3, caspase-8
and caspase-11 mRNA did not differ significantly between tumor and non-tumor containing
ovaries. Similar results occurred for human OvCa. Protein expression by immunohis-
tochemistry paralleled mRNA expression and was qualitatively higher in tumors. Increased
protein expression of caspase-1, IL1β, and IL18 occurred in surface epithelium, tumor cells,
and immune cells. The aryl hydrocarbon receptor (AHR), a potential tumor suppressor and
NLRP3 regulator, was higher in hen (2.4x increase, p = 0.002) and human tumors (1.8x
increase, p = 0.038), suggesting a role in OvCa. Collectively, the results indicate that inflam-
masome expression is associated with hen and human OvCa, although the NLR sensor
type remains to be determined.
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Introduction
Chronic inflammation is associated with cancer risk and is an element of tumor development
[1–4]. There is increasing evidence that inflammasome formation promotes a chronic, pro-
inflammatory environment [5, 6]. However, the role of inflammasomes in cancer progression
remains unclear since inflammasome expression varies among tumor types and pro- and anti-
tumor effects occur in different cancers [6, 7].
Inflammasomes are large multi-protein complexes, composed of a sensor (receptor), an
effector and an adaptor protein that control the activation of caspase-1 [8]. Activated caspase-1
stimulates the production of IL1β and IL18. Inflammasomes are categorized based on their
sensor types and include NLRP1, NLRP3, NLRC4, AIM2, and NLRP6 [6], each activated by
different signals [9]. The NLRP3 inflammasome is the best-characterized inflammasome [10].
It is primarily cytoplasmic and contains the sensor NLR (nucleotide-binding oligomerization
domain [NOD]-like receptors), the adaptor protein ASC (apoptosis-associated speck-like pro-
tein containing a caspase activation and recruitment domain) and the effector protein caspase-
1. The NLRP3 inflammasome has a broad range of activators such as dsRNA, extracellular
ATP or asbestos [11]. NLRP3 inflammasome assembly activates caspase-1 which then converts
pro-interleukin-1β (IL1β) and pro-interleukin-18 (IL18) to active IL1β and IL18 [5, 8]. IL1β
and IL18 are apex regulators of pro-inflammatory pathways. A consequence of inflammasome
activation is pyroptosis, a form of programmed lytic cell death that is distinct from apoptosis
[12].
The NLRP3 inflammasome is involved in tumor development, although the precise role of
the NLRP3 inflammasome is unclear [9, 13] since the cytokines it produces suppress some
cancers, while they facilitate tumorigenesis of other cancers. For example, in hepatocellular
carcinoma, patients with low expression levels of NLRP3 inflammasome components had a
worse prognosis [14]. Colitis-associated cancer was higher in NLRP3 knockout mice models;
the increased tumor burden was correlated with attenuated levels of tumor IL-1β and IL-18
[15]. In contrast, increased NLRP3 inflammasome activity promotes skin and breast cancer
[7]. There is no information on inflammasome expression in ovarian tumors.
The molecular regulation of the NLRP3 inflammasome involves both positive and negative
regulatory pathways, and regulation occurs at the transcriptional and post-translational levels
[10, 16]. The aryl hydrocarbon receptor (AHR) negatively regulates NLRP3-mediated caspase-
1 activation and IL-1β secretion in macrophages by inhibiting NLRP3 transcription [17]. AHR
expression is increased in multiple cancers [18]. It is expressed in human ovarian cancer, and
the endogenous AHR ligand, 2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid methyl
ester (ITE), inhibits ovarian cancer cell proliferation and migration in vitro [19]. In turn the
tumor suppressor AHRR (aryl hydrocarbon receptor repressor) inhibits AHR and reduces
inflammation and cancer progression [18, 20]. In normal cells, AHR activation induces AHRR
which then negatively regulates AHR. In cancer cells, the AHRR-AHR feedback loop is inter-
rupted by methylation of the AHRR promoter which blocks its expression. The absence of
AHRR results in the induction of genes associated with tumorigenesis and cancer progression
[20].
The study objective was to determine if the NLRP3 inflammasome components (NLRP3,
caspase-1), and the corresponding cytokine products, IL1β and IL18, were increased in ovarian
tumors. AHR and AHRR were assessed to determine if the expression correlated with the
inflammasome in ovarian cancer. We used the hen, an animal model of spontaneous human
ovarian cancer, that has been shown to have validity as a model of ovarian cancer based on his-
tological, biochemical and immunologic similarities to human ovarian cancer [21–25]. The
Human Protein Atlas suggests human ovarian tumors express NLRP3, caspase-1, IL1β and
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IL18 [26, 27]. But there is limited experimental information on expression of NLRP3 inflam-
masomes in human ovarian tumors. Therefore human samples were examined for comparison
to observations in hen ovaries to provide an indication of the generalizability of hen results to
human OvCa.
Materials and methods
Tissues: White Leghorn hens (3 years old, strain W96) were housed at the poultry farm of the
University of Illinois at Urbana-Champaign, Department of Animal Science. Food and water
were provided ad libitum, and hens were maintained on a 17:7 hours (light: dark) schedule.
Ovarian morphology was evaluated using transvaginal ultrasound as described previously
(26); the data were used to select hens with normal ovaries (n = 8) or ovarian tumors (n = 10).
Transvaginal ultrasound is not associated with pain or suffering and does not require anesthe-
sia or analgesia. Hens were rapidly euthanized by standard cervical dislocation and the ovaries
were removed and immediately placed in ice-cold phosphate buffered saline (PBS; pH 7.4).
This study complied with the recommendations of the Guide for the Care and Use of Labora-
tory Animals of the National Institutes of Health [28]. The Institutional Animal Care and Use
Committees at Rush University Medical Center (number 08–011) and the University of Illinois
(number 05147) approved the study protocol.
Human tissue for mRNA from patients with normal (n = 4) ovaries or ovarian tumors
(n = 8) was obtained with written informed consent following a protocol approved by the
Internal Review Board at Rush University Medical Center during December 2004 through
February 2009. The inclusion criteria were primary epithelial ovarian cancer from previously
untreated patients undergoing debulking surgery. The average age of the cancer patients was
60±9 years. The sample is representative of the Chicago area population. The demographics of
the cancer patients is shown in S1 Table. For mRNA controls, normal ovarian tissue was
obtained from patients (ages 30–70) following complete hysterectomy from the National Dis-
ease Research Interchange (NDRI) without patient demographic data.
For immunohistochemistry, human tissue arrays containing cancer and control tissue were
obtained commercially (catalogue numbers T111, T112a, T112b, MC241, OV242, T114,
T113a, OV802at; US BioMax, Derwood, MD). Normal tissue sections were from a combina-
tion of cancer adjacent areas (1.5 cm away from tumor), and normal non-cancer containing
ovaries (unmatched). Patient characteristics were provided by US BioMax (S1 Table). US Bio-
Max obtained written informed consent. Information on the population of origin represented
by the commercial arrays was not available from US Biomax, and thus, its application to the
general population is not known. For this study, the inclusion criteria were primary epithelial
ovarian cancer from previously untreated patients undergoing debulking surgery; exclusion
criteria included germ cell or other stromal tumors.
Protein analysis by histology and immunohistochemistry
Ovaries were fixed in PBS-buffered formalin (10%) and embedded in paraffin. Hematoxylin
and Eosin (H&E) stained sections of ovary were analyzed for tumor type and stage based on
similarities to human morphology, as we established in a previous report (28). In summary,
early stage (I and II) tumors are confined to the ovary (stage I) or ovary and oviduct (stage II).
Later stage tumors (III and IV) have local abdominal and peritoneal metastases with ascites
(stage III) or distant metastases with profuse ascites (stage IV).
Protein expression was assessed by immunohistochemistry using the ABC method (Vectas-
tain) in sections of human and hen ovarian and tumor tissue. Primary antibodies to human or
chicken antigens (S2 Table) were used according to the manufacturer’s recommendations
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after establishing optimal dilutions. Characterization of normal and tumor ovary structures
was based on our prior studies of ovarian tumor histology [23] and immune cells [24] in the
hen. Briefly, the nuclei of tumor cells tend to show signs of activation such as enlarged nuclei,
coarse chromatin with aggregates, etc. Immune cells were identified as “putative” immune
cells based on morphology and an irregular distribution within the stroma and tissue layers.
Sections were immunostained using a kit with diaminobenzidine (DAB) as a substrate
(Vector Labs, Burlingame, CA). Sections were washed (15 minutes), counterstained with
Hematoxylin (Fisher Scientific, Rockford, IL), dehydrated, applied to slides, and dried (37˚C,
16 hours). In preliminary procedures, sections of spleen and liver were assessed as positive
controls to evaluate antibodies. Microscopy was performed on a Zeiss Axiovert or an AmScope
B120 light microscope. Images were captured digitally. A pathologist reviewed the images.
mRNA analysis
Human and chicken mRNA were measured by qRT-PCR as described previously (29–32).
RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA). The 260/280 absorbance
ratio was used to assess RNA concentration and quality. Total RNA was treated with DNAse
to remove genomic contamination, and 1.0 μg was used for first strand synthesis using a High
Capacity cDNA Reverse transcription kit (Applied Biosystems Inc, Foster City, CA. Primers
(S3 Table) were based on genes from the NCBI database; chicken primers were orthologues of
human genes. Oligoperfect Designer software (Invitrogen; Carlsbad, CA) was used to design
each primer and the endogenous actin control. 25 ng of the first strand was used for each PCR
reaction as template. PCR comprised initial denaturation at 94˚C for 3 minutes, followed by
35 cycles (each cycle at 94˚C for 30 seconds, 57˚C for 30 seconds and 72˚C for 1 minute). PCR
amplicons were separated in a 3% agarose gel and stained with ethidium bromide. The PCR
product was purified (QIAquick PCR purification kit; Qiagen, Valencia, CA) and then
sequenced (DNA sequencing facility, University of Illinois at Chicago; ABI BigDye Terminator
in an ABI 3100 Genetic analyzer, Applied Biosystems Inc, Foster City, CA) using the same
primers. The contour quantities of bands in gels (density of the band multiplied by the area of
the band) were measured using Quantity One software (BioRad, Hercules, CA). The contour
quantities of actin bands were used to normalize the contour quantities of other bands.
Quantitative Reverse Transcriptase-PCR (qRT-PCR) was carried out using SYBR green
master mix in an ABI 7500 RT-PCR system and analyzed using the ΔCt method with chicken
Actin as an internal control (Applied Biosystems). The ΔΔCt was determined by subtracting
ΔCt of each sample from the average ΔCt of a normal ovary standard. The differences in
mRNA expression levels were calculated as the fold change using the formula 2-ΔΔCt [29].
mRNA expression is the mean fold change (mFC) relative to normal tissue.
Statistical analyses
Statistical tests were done using GraphPad Prism or SPSS (Chicago, IL). The Mann Whitney U
test was used to determine if mean differences were significant with p<0.05 considered signifi-
cant. Spearman correlation analysis was used to assess relationships between mRNA levels for
MRC1LB vs. NLRP3 and for caspase-1 vs. IL1β.
Results
Characterization of normal and tumor-containing ovaries
Examples of the histology of ovaries determined to be normal or to contain a tumor by ultraso-
nography are shown in Fig 1. Normal ovaries contain developing follicles ranging from small
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primary to large pre-ovulatory follicles. Ovaries with tumors have few or no follicles and
numerous degenerating follicles. All the ovaries classified as tumor-containing by ultrasound
had either no follicles or variable follicle numbers. Follicles found in tumor-containing ovaries
were typically not well developed or showed signs of degeneration.
Tumor-containing ovaries stained intensely and extensively for EpCAM by immunohis-
tochemistry (Fig 2). EpCAM stain in normal ovaries was limited to surface epithelial cells (Fig
2A & 2B). In contrast, stain occurred on surfaces of tumor cells arranged in cords within the
tumor stroma (Fig 2C & 2D).
Increased immune cell content is a hallmark of tumors. T cell mRNA expression was higher
overall (CD3d, p = 0.003; CD45, p = 0.006; CD4, p = 0.0006), and there was a dramatic increase
in chB6 (B cell) mRNA (median increase 23x; p = <<0.0001) in hen tumors compared to nor-
mal ovary as we described previously [24]. Among T cell subsets, the expression of CD8a
(p = 0.055) approached significance but CD8b (p>0.5) did not differ significantly from expres-
sion in the normal ovary. MRC1L-B, a homologue of the mammalian mannose receptor iden-
tifies chicken macrophages [30]; MRC1L-B mRNA was 2-fold higher in tumor-containing
ovaries (p = 0.002).
Inflammasome mRNA expression
The changes for the inflammasome mRNAs were parallel in chicken and human and ovaries
and tumors. In hen ovaries (Fig 3), caspase-1 mRNA was 5.9x higher (p = 0.04) in tumors than
in normal ovaries. Furthermore, caspase-1 was correlated with IL1β (r = 0.74, p = 0.046) in
Fig 1. Hen ovary with and without tumors stained with H&E. (A) normal ovary with developing follicles (f); (B) normal ovary showing surface epithelium (SE) and
cells with resting nuclei (arrows) in stroma (s); (C) ovary with ovarian tumor has degenerating follicles (f); (D) activated nuclei (arrows) in mucinous tumor showing
[inset, low magnification showing overall morphology]; (E) serous tumor; (F) higher magnification of E showing activated nuclei (arrows). Original magnification: (A)
4X; (B) 4X [inset, 40X]; (C) 10X; (D) 40X [inset, 4X]; (E) 10X; (F) 40XTumors commonly have a proliferative cell profile. Consistent with the ultrasound designation,
several indicators of proliferation, PCNA (Proliferating Cell Nuclear Antigen) (p = 0.04), WT1 (Wilms Tumor 1 protein) (p = 0.012) and EpCAM mRNA (3.7x;
p = 0.0001) were significantly higher in ovarian tumors compared to normal ovaries in the hen.
https://doi.org/10.1371/journal.pone.0227081.g001
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tumor-containing hen ovaries. Caspase-8 was assessed for comparison since it has a central
role in apoptosis (35, 36); it did not differ (p = 0.2) between normal and tumor containing ova-
ries. Caspase-11 drives an alternate NLRP3 pathway (37) and did not vary (p = 0.6). Although
the mean difference was 18% higher in ovarian tumors, changes in NLRP3 mRNA did not
reach statistical significance (p = 0.3). The mRNA expression of the inflammasome products
IL1β (4x; p = 0.02) and IL18 (7.8x; p = 0.0003) was increased significantly in hen tumors com-
pared to normal ovary. Inflammasome responses usually are associated with macrophages.
Although NLRP3 expression did not increase significantly, as expected it was highly positively
correlated with the macrophage marker MRC1LB (r = 0.90, p = 0.005).
Similar to the chicken, CASP1 (2.7x; p = 0.05), IL1β (4.9x; p = 0.04) and IL18 (33x; p = 0.02)
mRNA were significantly higher in human ovarian tumors (Fig 4). NLRP3 increased 1.2x
(p = 0.06) but the difference from normal ovary did not reach significance.
AHR and AHRR mRNA expression
AHR (2.4x, p = 0.002) and AHRR (2.7x, p = 0.4) expression were higher in hen ovaries with
tumors compared to normal ovaries (Fig 3). Similarly, AHR (1.8x, p = 0.04) and AHRR (3.7x,
p = 0.004) expression were higher in human tumors compared to normal ovaries (Fig 3).
The changes in mRNA expression in ovarian cancer relative to control are summarized for
the chicken and human in Fig 5.
Inflammasome protein expression
NLRP3 staining was not evident in normal ovaries (Fig 6A). There was light and diffuse cyto-
plasmic staining for NLRP3 in tumor stromal cells, with little or no staining of surface epithe-
lial cells (Fig 6C and 6D). The cytoplasm of small groups of individual cells that resemble
Fig 2. EpCAM expression in hen ovaries with and without tumors. (A) normal ovary expresses relatively little
EpCAM, (B) EpCAM is highly expressed in normal ovary surface epithelium (SE); inset shows intense stain [white
arrow] at higher magnification, (C) tumor cells express EpCAM (arrows), (D) higher magnification of ovarian tumor
shows EpCAM is expressed primarily on membranes (arrows). Original magnification: (A) 4X; (B) 4X [inset, 40X]; (C)
4X; (D) 40X.
https://doi.org/10.1371/journal.pone.0227081.g002
Inflammasomes in ovarian cancer
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Fig 3. Dot plot of mRNA levels in hen normal ovary (normal) and ovarian cancer (CA). EpCAM, a proliferation
marker, differed significantly (p<0.001). MRC1L-B, a marker for macrophages, differed significantly (p = 0.002). The
Inflammasomes in ovarian cancer
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infiltrating immune cells stained for NLRP3 (Fig 6C). These cells had variable levels of diffuse
and dark punctate cytoplasmic stain.
Caspase-1 expression was limited in normal ovaries to the surface epithelium and the layer
immediately under the surface epithelium (Fig 7A and 7B). In tumor ovaries, caspase-1 stain-
ing was intense throughout the section. Staining in the cytoplasm of presumed immune cells
varied from diffuse to punctate bodies (Fig 7C–7F). In tumor cells, caspase-1 staining occurred
in the cytoplasm, occasional peri-nuclear sites and some punctate cytoplasmic structures (Fig
7E and 7F).
difference between mRNA of inflammasome components differed significantly for caspase-1 (CASP1) (p = 0.04), IL1β
(p = 0.04) and IL18 (p = 0.003) but not NLRP3 (p = 0.3) between normal and cancer ovaries; other caspase mRNAs
caspase-8 (CASP8) (p = 0.17) and caspase-11 (CASP11) (p = 0.65) did not differ. AHR (p = 0.002) but not AHRR
(p = 0.5) mRNA expression differed between normal and cancer ovaries. Note: Y-axis range differs among graphs;
values are mean fold change relative to actin ± SEM.
https://doi.org/10.1371/journal.pone.0227081.g003
Fig 4. Dot plot of mRNA levels in human normal ovary (normal) and ovarian cancer (CA). The differences for
mRNA of inflammasome components were significant for caspase-1 (CASP1) (p = 0.05), IL1β (p = 0.04) and IL18
(p = 0.04) but not NLRP3 (p = 0.06). AHR (p = 0.038) and AHRR (p = 0.04) mRNA levels differed significantly. Note:
Y-axis range differs among graphs; values are mean fold change relative to actin ± SEM.
https://doi.org/10.1371/journal.pone.0227081.g004
Inflammasomes in ovarian cancer
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Little IL1β staining of the normal ovary was seen although there were patches of faint stain
adjacent to the surface epithelium (Fig 8A). IL1β was expressed predominantly in clusters of
cells that resembled migrating immune cells throughout the stroma of tumor ovaries (Fig 8B
Fig 5. Summary of changes in mRNA expression shown as the ratio of cancer/normal values for NLRP3, caspase-1,
IL1β, IL18, AHR and AHRR in (left) hen and (right) human ovaries to show the relative changes. Note: Y-axis range
differs between graphs.
https://doi.org/10.1371/journal.pone.0227081.g005
Fig 6. NLRP3 expression in hen ovary with and without tumors is low. (A) normal ovary without NLRP3
expression; (B) control tumor section without primary antibody is not stained; (C) immune cells in a tumor ovary
stain for NLRP3; inset shows punctate cellular stain (arrow); (D) tumor cells are occasionally lightly stained (white
arrow). Original magnification: (A) 10X; (B) 10X; (C) 10X [inset, 40X]; (D) 4x.
https://doi.org/10.1371/journal.pone.0227081.g006
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and 8C). There were also random areas of light stromal cell/tumor cytoplasmic staining (Fig
8B). No IL1β staining occurred in control sections when the primary antibody was omitted
(Fig 8D).
IL18 rarely was expressed in the normal ovary except in the surface epithelium (Fig 9A and
9B). In tumors, IL18 staining was strong and occurred throughout the tissue, in tumor cell
cytoplasm with various intensities in ovarian cells and immune cells (Fig 9C–9F). Also,
some material that appears to be secreted was evident as extracellular strands and aggregates
(Fig 9F).
Inflammasome components also were expressed in human ovarian tumors. NLRP3 staining
was negligible or faint in tumor stroma and stronger in scattered cells throughout the tissue
(Fig 10). Caspase-1 staining was intense in most stages and types of tumor cells, with punctate
stain around nuclei and on some cell surfaces (Fig 11). Moderate to light IL1β staining
occurred fairly uniformly in tumor cell cytoplasm (Fig 12). IL18 stained cells were scattered
through tumor stroma and adjacent to the tumor edge (Fig 13). Minimal expression of
NLRP3, caspase-1, IL1β, or IL18 occurred in normal tissue (Figs 10–13).
Discussion
The expression of caspase-1, IL1β, and IL18, hallmark indicators of inflammasome expression,
was higher overall in the presence of tumors in hen and human ovaries compared to normal
ovaries. This finding is important since inflammasomes are a druggable target. Drugs targeting
the inflammasome could reduce inflammation and cancer progression [13]. In summary, the
protein expression of the inflammasome components detected by immunohistochemistry
occurred in both immune cells and tumor cells. Expression patterns of protein were similar in
Fig 7. More caspase-1 is expressed in hen ovary with tumors than in normal ovary. (A) normal ovary without stain in follicles (f) or stroma (s); (B) normal ovary
shows surface epithelium (arrow) staining; (C, E) intense stain in cords of tumor cells; (D, F) higher magnification shows perinuclear (arrow) and diffuse
cytoplasmic stain (white arrow) [inset, punctate perinuclear stain (arrow)]. Original magnification: (A) 4X; (B) 4X; (C) 4X; (D) 40X; (E) 4X; (F) 40X [inset, 60X].
https://doi.org/10.1371/journal.pone.0227081.g007
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chicken and human ovarian tumors. AHR, a potential inflammasomes regulator, was similarly
higher in hen and human ovarian cancer.
This is the first report of the general expression of inflammasomes in ovarian cancer.
Chang [31] used expression profiling to identify mechanisms involved in the malignant trans-
formation of endometriosis to ovarian cancer; 18 genes were identified, including NLRP3, IL-
1B, and IL-18, which implicated inflammasomes. They found a significant correlation between
the expression levels of the target genes and the progression-free patient survival; high expres-
sion levels of AIM2 and NLRP3 were significantly correlated with low progression-free
survival.
The mRNA and protein expression results were correlated qualitatively for each of the mea-
sures. For example, caspase-1 mRNA expression was dramatically higher, and the protein
expression detected by anti-caspase-1 antibody was intense in human and hen tissue. How-
ever, within each tissue section, the expression was not uniform; it varied by cell type and areas
within the sections. In some cases, such as for IL18, immune cells stained intensely by immu-
nohistochemistry while ovarian tumor cell cytoplasm stained moderately.
For caspase-1 and IL18, the pattern of stained cells was similar in hen and human tumor tis-
sue. The results for IL1β were similar except that human tumor tissue stained more often than
in the hen, which might be explained by differences in the antibody efficacy for hen and
human immunohistochemistry. Also, samples were selected randomly from the hen ovary for
different analyses. Since the tissue is not homogeneous, samples from ovaries with earlier stage
tumors may not have similarly represented tumor cells, which could potentially contribute to
Fig 8. Hen ovary with and without tumors stained for IL1β. (A) normal ovary without stain except some faint
groups of cells [inset, higher magnification of A showing faint cells (arrow) near surface epithelium]; (B) stained
groups (arrows) of immune cells in tumor ovary; (C) immune cell groups in tumor stroma and higher magnification
inset showing punctate stain in cell cytoplasm (black arrow) and nuclear stain (white arrow); (D) control section of
tumor without primary antibody is not stained. Original magnification: (A) 4X [inset, 10X]; (B) 10X; (C) 4X [inset,
40X]; (D) 40X.
https://doi.org/10.1371/journal.pone.0227081.g008
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variations in the immunohistochemistry staining and differences between hen and human tis-
sue. Despite these considerations, the mRNA and protein results were remarkably similar,
both within hens and between hen and human ovaries.
NLRP3 mRNA and protein levels were low and did not differ between normal and tumor
ovaries. Although surprising in light of the elevated caspase-1, IL1β, and IL18, this is consistent
with other reports that NLRP3 expression is relatively low in various cell types [16]. However,
inflammasome reactions often occur in macrophages [32]. An influx of macrophages into
tumors is well documented [33–36] and we showed increased mRNA for the chicken macro-
phage marker in tumor ovaries. Although NLRP3 expression did not differ between normal
and tumor ovaries, NLRP3 levels were significantly correlated with the macrophage marker
MRCL1B.
A possible explanation for the lack of increased NLRP3 expression, despite elevated cas-
pase-1, IL1β and IL18, is that only specific locations have cells with activated NLRP3 (i.e., a
cluster of invading immune cells at the tumor/tissue interface) and tissue was from regions
without altered NLRP3. However, this is not likely since different samples were used for
immunohistochemistry and mRNA. Furthermore, the result was the same in hen and human.
Moreover, if the NLRP3 result were due to a technical issue, such as an ineffective antibody, or
an inappropriate PCR primer, then the results of hen and human and immunohistochemistry
and PCR would not be similar; a different anti-NLRP3 antibody was used for hen and human
immunohistochemistry and species-specific primers were used. There are several possible rea-
sons that NLRP3 expression did not differ between cancerous and non-cancerous tissue: (i) a
different NLR inflammasome (e.g., NLRP1 or NLRC4) is involved in IL18 production [37], or
Fig 9. IL18 expression in hen ovary with and without tumors. (A) normal ovary with no stain in stroma but abundant surface epithelium stain (arrow); (B)
higher magnification of A showing cytoplasmic cell staining in surface epithelium of normal ovary (arrow); (C) IL18 is expressed in cords of tumor cells (arrows);
(D) higher magnification shows staining is primarily cytoplasmic (white arrow) and along cell surfaces (black arrow and inset); (E) (left panel) blood vessel with
stained immune cells (arrow) and unstained nucleated red blood cells and (right panel) higher magnification of same area; (F) some tumor areas have extracellular
(presumably secreted) IL18 which appears as aggregates and single points in extracellular spaces (black arrows) as shown at higher magnification inset. Original
magnification: (A) 10X; (B) 40X; (C) 10X; (D) 40X; (E) 4X, left, 40X, right; (F) 4X [inset, 40X].
https://doi.org/10.1371/journal.pone.0227081.g009
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(ii) low-level NLRP3 expression leads to caspase-1 activation without significant synthesis
[32]. Increased expression of NLRP1 occurs in breast cancer, and its transfection into cell lines
promotes proliferation [38]. NLRP1, but not NLRP3, promotes melanoma (42). Although an
Fig 10. NLRP3 stain is minimal in human OvCa; (A) normal ovary; (B and C) occasional stained cells (arrow)
associated with tumor; (D) higher magnification of (C) showing aggregated cytoplasmic stain. Original magnification:
(A) 4X; (B) 4X; (C) 10X; (D) 40X.
https://doi.org/10.1371/journal.pone.0227081.g010
Fig 11. Caspase-1 expression occurs in tumor cells and immune cells in multiple human ovarian tumor types. (A) normal ovary without stain; (B)
serous OvCa has punctate (arrow) and diffuse (white arrow) cytoplasmic stain in tumor cells; (C) serous OvCa showing dark stain in immune cells
(arrows) among lighter stained tumor stroma; (D) serous OvCa showing punctate (arrow) and diffuse cytoplasmic (white arrow) stain in tumor cells;
(E) diffuse cytoplasmic stain in mucinous OvCa; (F) light stain in clear cell tumor (arrows); (G) endometrioid tumor staining primarily in immune
cells (arrows); (H) endometrioid tumor cell stain in cords (arrow) [inset, higher magnification shows tumor cell cytoplasmic stain (arrow)]. Original
magnification: (A) 4X; (B) 10X [inset, 40X]; (C) 4X; (D) 40X; (E) 10X; (F) 4X; (G) 4X; (H) 4X [inset, 40X].
https://doi.org/10.1371/journal.pone.0227081.g011
Inflammasomes in ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0227081 January 10, 2020 13 / 19
NLRP1-like gene occurs in the hen [39], it was not possible to evaluate NLRP1 expression at
this time since appropriate reagents are currently not available.
In response to specific stimuli, NLR expression is thought to be regulated in two steps.
There are also canonical and non-canonical activation pathways. Canonical activation of the
NLR inflammasome in response to a stimulus involves transcription and then oligomerization
which proceed independently [40, 41]. Non-canonical NLR activation also involves transcrip-
tion and oligomerization [40]. The primary caspase in canonical and non-canonical activation
of IL18 production differs; canonical activation involves caspase-1 while non-canonical activa-
tion proceeds through caspase-11 (mouse)/caspase-4,5 (human) [41]. Factors and mechanisms
in priming and activation remain to be clarified for most inflammasomes including NLRP3.
For example, contrary to the initial models based on macrophage studies, in which the acti-
vated NLRP3 inflammasome is an oligomer of NLRP3, Salmonella simultaneously activates
two NLRs, NLRP3 and NLRC4, and both are required in the same inflammasome oligomer to
stimulate IL-1β processing [42]. In the current study, caspase-1 expression was significantly
elevated while caspase-11 (non-canonical NLRP3 activation pathway) and caspase-8 (apopto-
sis pathway) did not change, suggesting activation of the canonical NLR pyroptosis pathway.
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that regu-
lates biological responses to aryl hydrocarbons, such as dioxin and dioxin-like compounds.
It is present in various species and controls xenobiotic-metabolizing enzymes such as cyto-
chrome P450s, principally CYP 1A1 [43]. AHR also has a role in immune function including,
for example, in the generation of regulatory T cells, and control of the balance between Treg
and Th17 cell differentiation [44]. AHR signaling has a critical function in carcinogenesis;
AHR null mice lacking AHR developed liver tumors more frequently after exposure to a
hepatic carcinogen (diethylnitrosamine), compared to wild type mice [45].
Fig 12. IL1β expression in human tumor and immune cells. (A) normal ovary is unstained; (B) very lightly stained
cells (arrow) at a tumor edge; (C) stained tumor cells (arrow); (D) stained cells of C at higher magnification showing
cytoplasmic (arrow) stain. Original magnification: (A) 10X; (B) 10X; (C) 10X; (D) 40X.
https://doi.org/10.1371/journal.pone.0227081.g012
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AHR is expressed in the human ovary and its expression does not vary during the men-
strual cycle or with age [46]. Birds, including chickens, also express AHR [47, 48]. AHR has a
role in follicle development and steroid hormone production since there are fewer advanced
follicles and lower sex steroid production in AHR knockout mice [46].
AHR is constitutively activated in many cancers [49]. In human ovarian cancer, there is
one report that AHR mRNA was not changed in primary tissue [46], while another study
found that AHR expression was elevated in ovarian cancer cell lines [19]. We found that AHR
expression was greater in human and chicken ovarian cancer.
AHRR represses AHR and may act as a tumor suppressor; reduced expression was reported
in malignant ovarian tissue, and it is hypermethylated in OvCa [20]. AHRR is conserved in the
chicken relative to the negative regulation of AHR and ERα activities, but functional mecha-
nisms may differ among mammalian and fish homologs [48]. We found AHRR was elevated
in human and chicken OvCa although it was only significant in the human tumors.
Conclusions
Collectively, the data show that inflammasome components were higher in both hen and
human OVCA. Inflammasome expression appears in immune cells and tumor cells. The spe-
cific NLR sensor remains to be determined since NLRP3 did not differ in ovarian tumors and
normal ovary. Also, AHR expression increased similarly in hen and human tumors. Immune
reactions may differ during the development and progression of a tumor and it is possible that
additional or different reactions may be a response to a tumor. While the mechanisms
involved in inflammasome effects on tumorigenesis remain to be determined, this study sets a
platform for examining the relationship between tumor initiation and early inflammatory
Fig 13. IL18 expression occurs predominantly in immune cells in human ovary with tumors. (A) unstained normal
ovary; (B) stained cells in tumor section without hematoxylin stain; (C) stained immune cells among tumor cells; (D)
enlarged selection from image C at higher magnification to show cytoplasmic stain of invading presumptive immune
cells. Original magnification: (A) 4X; (B) 10X; (C) 10X; (D) 40X. Arrows indicate immune cells.
https://doi.org/10.1371/journal.pone.0227081.g013
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events in ovarian cancer development. Furthermore, the chicken model has potential use for
pre-clinical testing of therapeutics targeting inflammasomes.
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